By Fineline Cube 
U.S. biopharma leader AbbVie Inc. (NYSE: ABBV) released its third‑quarter fiscal‑2025 results. Net revenues rose 8.4% YoY to USD 15.78 billion (constant‑currency), while diluted earnings per share (EPS) fell sharply to USD 0.10, a ‑88.6% decline. Adjusted diluted EPS slipped 38% to USD 1.86 after the company accounted for acquired IPR&D and milestone expenses tied to recent large‑scale purchases.
Key Financial Highlights
| Metric (Q3 2025) | Amount (USD) | YoY Change |
|---|---|---|
| Net Revenue | 15.78 bn | +8.4 % |
| Diluted EPS | 0.10 | ‑88.6 % |
| Adjusted Diluted EPS | 1.86 | ‑38 % |
| Full‑Year Adjusted EPS Guidance (revised) | 10.61 – 10.65 | ↑ from 10.38 – 10.58 |
All revenue figures are presented in constant‑currency terms.
Revenue Drivers by Product
- Skyrizi (risankizumab) – USD 4.7 bn, +46 % YoY (auto‑immune therapy)
- Rinvoq (upadacitinib) – USD 2.2 bn, +34.1 % YoY (auto‑immune & inflammatory)
- Botox Therapeutic – USD 985 mm, +15.8 % YoY
- Ubrelvy (ubrogepant) – USD 354 mm, +31.5 % YoY (migraine)
Negative contributor: Humira (adalimumab) revenue fell 55.7 % to USD 993 mm as biosimilar competition intensifies.
Business‑Unit Performance
| Business Unit | Q3 2025 Revenue (USD) | YoY Growth |
|---|---|---|
| Immunology | 7.9 bn | +11.2 % |
| Neuroscience | 2.94 bn | +19.6 % |
| Oncology | 1.7 bn | ‑1.3 % |
| Aesthetics | 1.19 bn | ‑4.2 % |
Recent Acquisitions & Their Impact
| Acquisition | Deal Size (USD) | Close Date | Strategic Rationale |
|---|---|---|---|
| ImmunoGen | 10.1 bn | Feb 2024 | Expand antibody‑drug conjugate pipeline |
| Nimble Therapeutics | 200 mm | Jan 2025 | Early‑stage immunology assets |
| Capstan Therapeutics | 2.1 bn | Jun 2025 | Enhance oncology pipeline & novel targets |
The USD 2.05 per‑share hit to full‑year adjusted EPS reflects acquired IPR&D and milestone expenses from the above deals.
Outlook
- Guidance Upgrade: Full‑year adjusted diluted EPS now projected at USD 10.61 – 10.65, reflecting resilient top‑line momentum despite the EPS dip.
- Focus Areas: Continued emphasis on Skyrizi growth, Rinvoq expansion, and integrating newly acquired platforms to offset the decline in Humira sales.
Forward‑Looking Statements
This briefing contains forward‑looking statements that involve risks and uncertainties, including product development, regulatory approvals, integration of acquisitions, and market conditions. Actual results may differ materially from those expressed herein.-Fineline Info & Tech